Lineage Cell Therapeutics Files Proxy Supplement
Ticker: LCTX · Form: DEFA14A · Filed: Jun 11, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | DEFA14A |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, sec-filing
Related Tickers: LCTX
TL;DR
LCTX filed proxy docs, no new fee. Shareholders get more info for the annual meeting.
AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) is filing a Definitive Additional Materials document (DEFA14A) on June 11, 2025, supplementing its proxy statement for the 2025 Annual Meeting. This filing concerns the company's proxy materials and does not require a separate filing fee.
Why It Matters
This filing provides updated or additional information to shareholders regarding the upcoming annual meeting, ensuring they have the necessary details for voting on corporate matters.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to proxy materials for an annual meeting, not indicating any immediate operational or financial risk.
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Registrant
- 2025 (date) — Annual Meeting Year
- June 11, 2025 (date) — Filing Date
FAQ
What type of filing is this DEFA14A for Lineage Cell Therapeutics, Inc.?
This DEFA14A is a Definitive Additional Materials filing, supplementing the proxy statement for the 2025 Annual Meeting.
When was this filing submitted to the SEC?
The filing was submitted on June 11, 2025.
Does Lineage Cell Therapeutics, Inc. need to pay a filing fee for this document?
No, the filing indicates that no fee is required for this document.
What is the primary purpose of a DEFA14A filing?
A DEFA14A filing is used to provide definitive additional materials to shareholders related to a proxy statement, often after preliminary materials have been filed.
What is the business address of Lineage Cell Therapeutics, Inc.?
The business address is 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 11, 2025 regarding Lineage Cell Therapeutics, Inc. (LCTX).